Terumo BCT announces strategic collaboration with Cognate BioServices

Monday October 3, 2016 0 comments Tags: Lakewood, Terumo BCT, Cognate BioServices, Kelly Ganjei, Dave Flaten, Quantum Cell Expansion System

LAKEWOOD --Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, announced a strategic collaboration with Cognate BioServices to support the development of cell and immunotherapy products.Terumo_BCT_logoUSE

Terumo said Maryland-based Cognate is a leader in current good manufacturing practices (cGMP) and provides regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products and therapies.

Through this strategic collaboration, Cognate will become a Terumo BCT-trained center for development and contract manufacturing utilizing the Quantum® Cell Expansion System, the company said.

The Quantum system is used for preclinical and clinical manufacturing of adherent and non-adherent cell types including, but not limited to, mesenchymal stem cells (MSCs), neural stem cells (NSCs), endothelial cells, fibroblasts and T-cells, as well as for viral vector production.

Terumo said the collaboration allows organizations to conduct rapid proof-of-concept studies by using the Quantum system. In addition, the Quantum system allows for quick transition from a manual process into a functionally closed, customizable and automated manufacturing environment.

“We are delighted to be working with Terumo BCT,” said Kelly Ganjei, Cognate CEO. “Their long history of automating the handling of blood products is a great fit with our team, which has been at the forefront of large-scale contract manufacturing for therapeutic products derived from blood and other sources.

“This collaboration is especially timely in light of the tidal wave of immunotherapy products at our doorstep, and we look forward to being able to expand our offering of innovative technologies to our current and future clients.”

“This collaboration is a game changer because it replaces a manual process which can be burdensome,” said Dave Flaten, VP of Terumo’s Cell Therapy Technologies.

“The Quantum system has been on the market for more than five years, and organizations moving into clinical trials need the support of a leading contract manufacturing organization like Cognate to scale their manufacturing goals.”